HMOX1 and COVID-19: suggested that serum HO-1 concentrations upon hospital admission of COVID-19 patients could be a useful biomarker for clinical management, proposing that the increase of HO-1 in the early stage of the disease could be beneficial, as it would provide protection against oxidative stress and inflammation (249).